Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Raymond James Financial, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $288.03 (market cap $39.89B), while Raymond James Financial, Inc. trades at $168.52 (market cap $32.76B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Raymond James Financial, Inc. pays a 1.28% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | RJF | |
|---|---|---|
Market Cap | $39.89B | $32.76B |
Sector | Health | Financials |
52-Week High | $491.22 | $176.43 |
52-Week Low | $278.09 | $140.89 |
Enterprise Value | $38.15B | — |
Dividend Yield | — | 1.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Raymond James Financial (RJF) trades at $168.12, down 0.36% today, with a bullish technical signal and strong earnings momentum after beating estimates in three consecutive quarters. Revenue growth is robust, with 2025 revenue reaching $13.84B and net income of $2.14B, though profit margins have moderated slightly. Analyst consensus is positive with a $176.83 price target, and the company maintains a solid dividend, recently declaring $0.54 per share payable in July 2026.
The outlook for RJF is favorable, supported by earnings beats and strategic investments, but risks include rising expenses and market volatility. Upside potential exists if cost management improves and revenue growth sustains, aligning with analyst targets. Key risks are competitive pressures and economic sensitivity, yet institutional sentiment remains bullish with no sell ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
